Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.
Positron-emission tomography (PET)
Prostate-specific membrane antigen (PSMA)
Radioligand therapy (RLT)
Radionuclides
Theranostics
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
11
2020
accepted:
05
11
2020
pubmed:
12
11
2020
medline:
4
8
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during these past two decades. Last year, the European Association of Nuclear Medicine (EANM) published the procedure guidelines for the safe clinical practice of Lutetium-177 (
Identifiants
pubmed: 33175360
doi: 10.1007/s12149-020-01549-5
pii: 10.1007/s12149-020-01549-5
pmc: PMC7680309
doi:
Substances chimiques
Antigens, Surface
0
Ligands
0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
879-883Références
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2138-2151
pubmed: 31267161
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):20-30
pubmed: 30229528
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139-147
pubmed: 30151743
J Nucl Med. 2020 Apr;61(4):563-569
pubmed: 31586001
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):8-10
pubmed: 30310953
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080
pubmed: 30474706
Clin Cancer Res. 1999 Oct;5(10):2674-81
pubmed: 10537328
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):889-900
pubmed: 30488099
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):1041
pubmed: 30569188
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2545-2557
pubmed: 31399803
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930
pubmed: 31134301
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1723-1732
pubmed: 31028426
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2289-2297
pubmed: 31350604
Semin Oncol. 2003 Oct;30(5):667-76
pubmed: 14571414
Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1739-1749
pubmed: 26048612
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1081-1091
pubmed: 30603987
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19
pubmed: 29905907
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544
pubmed: 31440799
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):31-37
pubmed: 28891033
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728
pubmed: 31758224
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):1988
pubmed: 31240331
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1756-1757
pubmed: 31115638
J Nucl Med. 2019 Sep;60(9):1301-1307
pubmed: 30796173
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39
pubmed: 30350010
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2280-2288
pubmed: 31332498
Eur J Nucl Med Mol Imaging. 2018 May;45(5):860-877
pubmed: 29335762
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):901-907
pubmed: 30617554